Timothy Rolph - Oct 25, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Scientific Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Oct 25, 2022
Transactions value $
-$591,666
Form type
4
Date filed
10/27/2022, 09:27 PM
Previous filing
Oct 7, 2022
Next filing
Nov 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $52.2K +8.2K +4.18% $6.36* 205K Oct 25, 2022 Direct F1
transaction AKRO Common Stock Options Exercise $50.9K +1.8K +0.88% $28.35 206K Oct 25, 2022 Direct F1
transaction AKRO Common Stock Sale -$480K -10.7K -5.16% $45.09 196K Oct 25, 2022 Direct F1, F2
transaction AKRO Common Stock Sale -$214K -4.76K -2.43% $45.03 191K Oct 26, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -8.2K -14.54% $0.00 48.2K Oct 25, 2022 Common Stock 8.2K $6.36 Direct F1, F4
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -1.8K -2.32% $0.00 75.8K Oct 25, 2022 Common Stock 1.8K $28.35 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 25, 2021, previously adopted by the reporting person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.14, inclusive.
F4 This option shall vest and become exercisable in 48 equal monthly installments, commencing on January 1, 2019.
F5 This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2020.